Voyageur Pharmaceuticals Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VYYRF research report →
Companyvoyageurpharmaceuticals.ca
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products.
- CEO
- Brent Willis
- IPO
- 2017
- Employees
- 6
- HQ
- Calgary, AB, CA
Price Chart
Valuation
- Market Cap
- $13.39M
- P/E
- -5.08
- P/S
- 548.01
- P/B
- 25.68
- EV/EBITDA
- -5.06
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -4359.03%
- Op Margin
- -10803.34%
- Net Margin
- -10796.29%
- ROE
- -313.14%
- ROIC
- -477.30%
Growth & Income
- Revenue
- $11.67K · 0.00%
- Net Income
- $-3,528,461 · -206605.39%
- EPS
- $-0.02 · -70.97%
- Op Income
- $-3,528,461
- FCF YoY
- -855.86%
Performance & Tape
- 52W High
- $0.24
- 52W Low
- $0.00
- 50D MA
- $0.09
- 200D MA
- $0.11
- Beta
- 0.33
- Avg Volume
- 7.33K
Get TickerSpark's AI analysis on VYYRF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VYYRF Coverage
We haven't published any research on VYYRF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VYYRF Report →